Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析

【英語タイトル】Akari Therapeutics Plc (AKTX) - Financial and Strategic SWOT Analysis Review

Single User(1名様閲覧用)USD300 ⇒換算¥31,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥63,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥94,500見積依頼/購入/質問フォーム

Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b – 9. The company’s pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari pipeline products include Coversin, Coversin LA, LTB4+C5, LTB4, LTBA LA, and bioamine inhibitors. The company operates in Switzerland, Israel, the UK and the US. Akari is headquartered in New York City, New York, the US.

Akari Therapeutics Plc Key Recent Developments

Nov 30,2018: Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
Nov 30,2018: Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
Nov 15,2018: Akari Therapeutics announces third quarter 2018 financial results
Sep 30,2018: Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies Data Supports Akari s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous

This comprehensive SWOT profile of Akari Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Akari Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Table of Contents

Section 1 – About the Company

Akari Therapeutics Plc – Key Information
Akari Therapeutics Plc – Overview
Akari Therapeutics Plc – Key Employees
Akari Therapeutics Plc – Key Employee Biographies
Akari Therapeutics Plc – Key Operational Heads
Akari Therapeutics Plc – Major Products and Services
Akari Therapeutics Plc – History
Akari Therapeutics Plc – Company Statement
Akari Therapeutics Plc – Locations And Subsidiaries
Akari Therapeutics Plc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Akari Therapeutics Plc – Business Description
Akari Therapeutics Plc – Corporate Strategy
Akari Therapeutics Plc – SWOT Analysis
SWOT Analysis – Overview
Akari Therapeutics Plc – Strengths
Akari Therapeutics Plc – Weaknesses
Akari Therapeutics Plc – Opportunities
Akari Therapeutics Plc – Threats
Akari Therapeutics Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Akari Therapeutics Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Ratio Definitions
About GlobalData
Contact Us

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Akari Therapeutics Plc, Key Information
Akari Therapeutics Plc, Key Ratios
Akari Therapeutics Plc, Share Data
Akari Therapeutics Plc, Major Products and Services
Akari Therapeutics Plc, History
Akari Therapeutics Plc, Key Employees
Akari Therapeutics Plc, Key Employee Biographies
Akari Therapeutics Plc, Key Operational Heads
Akari Therapeutics Plc, Other Locations
Akari Therapeutics Plc, Subsidiaries
Akari Therapeutics Plc, Key Manufacturing facilities
Akari Therapeutics Plc, Key Competitors
Akari Therapeutics Plc, SWOT Analysis
Akari Therapeutics Plc, Ratios based on current share price
Akari Therapeutics Plc, Annual Ratios
Akari Therapeutics Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Akari Therapeutics Plc, Performance Chart
Akari Therapeutics Plc, Ratio Charts

★調査レポート[Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析] (コード:DATA904C15097)販売に関する免責事項を必ずご確認ください。
★調査レポート[Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ